art will appreciate that any pharmaceutically acceptable buffer that maintains the ph of the formulation within a certain range may be used the ph range of such buffer is preferably between about 3 8 and about 5 0 and most preferably between 4 0 and 4 5 suitable buffers include but are not limited to acetate benzoate citrate formate lactate and tartrate buffers preferably lactate table 2 exemplifies the use of various buffers to stabilize the ph of formulations containing 10 mga ml of the compound in order to further improve stability of the active compound it is preferable that the oxygen content in the formulation be reduced this can be done by sparging the formulation solution with nitrogen argon or other non reactive gas and when the compositions of the invention are packaged in vials or similar containers containing a headspace using such inert gas for the headspace when the compositions of the invention are packaged so that they contain a headspace it is preferable that the oxygen content in the headspace be less than about 12 and most preferably less than about 8 oxygen may be removed by other methods including the use of a vacuum to remove air and oxygen other methods of oxygen removal will be apparent to those skilled in the art a preferred presentation of the composition aspects of the invention comprises the compound at a concentration of 10 mga ml this.